Cite
HARVARD Citation
Diem, L. et al. (2018). Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod. Therapeutic advances in neurological disorders. p. . [Online].